Published studies about mineralocorticoid receptor antagonists (antimineralocorticoids) or (so-called) antialdosterones appeared effective in SCD and all-cause mortality prevention.21 22 54 However, in a recent systematic review,21 adverse effects (hyperkalaemia, degradation of renal function and gynaecomastia) were significantly higher in the antialdosterone-treated group compared with placebo. Here, NR3C2 is linked to Hyperkalemia.